DNA encoding tumor necrosis factor inhibitory protein and its use

Abstract

Recombinant DNA encoding Tumor Necrosis Factor (TNF) Inhibitory Protein, or an active fragment thereof, is obtained. The TNF Inhibitory Protein has the ability to inhibit: (a) the binding of TNF to its receptors, and (b) the cytotoxic effect of TNF. TNF Inhibitory Protein and salts, functional derivatives and active fractions thereof can be used to antagonize the deleterious effects of TNF by eliminating TNF from the body, and to reduce the cytotoxic activity of TNF by binding to TNF and thereby to inhibit the binding of TNF to its receptors. The DNA may be in an expression vector. Host cells transfected with such an expression vector may be used to produce the TNF Inhibitory Protein.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] The present application is a divisional of U.S. application Ser. No. 09 / 414,609, filed Oct. 8, 1999, which is a divisional of U.S. application Ser. No. 08 / 474,691, filed Jun. 7, 1995, now U.S. Pat. No. 5,981,701, issued Nov. 9, 1999, which is a divisional of U.S. application Ser. No. 07 / 876,828, filed Apr. 30, 1992, now U.S. Pat. No. 5,695,953, issued Dec. 9, 1997, which is a continuation of U.S. application Ser. No. 07 / 243,092, filed Sep. 12, 1988, now abandoned. The present application is also related to U.S. application Ser. No. 07 / 563,151, filed Aug. 6, 1990, now U.S. Pat. No. 5,359,037, U.S. application Ser. No. 07 / 879,373, now U.S. Pat. No. 5,512,544, and U.S. application Ser. No. 08 / 126,016, now U.S. Pat. No. 5,811,261, all of which are progeny of said application Ser. No. 07 / 243,092.FIELD OF THE INVENTION [0002] This invention relates to substantially purified Tumor Necrosis Factor (TNF) Inhibitory Protein and salts, functional ...

AI Technical Summary

Benefits of technology

[0007] The present invention provides substantially purified TNF Inhibitory Protein which can antagonize the effects of TNF. This antagonism can

Problems solved by technology

But, quite clearly, both TNF-α and TNF-β have also effects which can be extensively deleterious.

However, therapy with murine monoclonal antibodies, especially if administered repetitively, may not always be advisable in humans.

Images